J. Kastelein

1.1k total citations
28 papers, 785 citations indexed

About

J. Kastelein is a scholar working on Surgery, Cancer Research and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, J. Kastelein has authored 28 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Surgery, 9 papers in Cancer Research and 8 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in J. Kastelein's work include Lipoproteins and Cardiovascular Health (17 papers), Cancer, Lipids, and Metabolism (9 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers). J. Kastelein is often cited by papers focused on Lipoproteins and Cardiovascular Health (17 papers), Cancer, Lipids, and Metabolism (9 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers). J. Kastelein collaborates with scholars based in Netherlands, United States and Australia. J. Kastelein's co-authors include Joep C. Defesche, Eric J.G. Sijbrands, Philip J. Barter, Alistair V.W. Nunn, Richard Hobbs, Marjolein Visser, Geesje M. Dallinga‐Thie, Erik S.G. Stroes, Karim El Harchaoui and Emily Cohen and has published in prestigious journals such as The Lancet, Nature Genetics and Journal of the American College of Cardiology.

In The Last Decade

J. Kastelein

27 papers receiving 758 citations

Peers

Countries citing papers authored by J. Kastelein

Since Specialization

Citations

This map shows the geographic impact of J. Kastelein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Kastelein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Kastelein more than expected).

Fields of papers citing papers by J. Kastelein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Kastelein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Kastelein. The network helps show where J. Kastelein may publish in the future.

Co-authorship network of co-authors of J. Kastelein

This figure shows the co-authorship network connecting the top 25 collaborators of J. Kastelein. A scholar is included among the top collaborators of J. Kastelein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Kastelein. J. Kastelein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	† Safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia	Journal of clinical lipidology	Stephen C. Nicholls, Adam Nelson et al.	1
2	†Obicetrapib Demonstrates Significant Reductions Of Lp(a) On Top Of High-intensity Statins	Journal of clinical lipidology	Andrew Hsieh, Xiaohong Yang et al.	1
3	Obicetrapib does not accumulate in adipose tissue: Results from studies in man and non-human primates	Atherosclerosis	J. Kastelein, Marc Ditmarsch et al.	1
4	Obicetrapib demonstrates significant reductions of Lp(a) on top of high-intensity statins	Atherosclerosis	Xiaohong Yang, Andrew Hsieh et al.	2
5	The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolemia Patients with Little to No Low-Density Lipoprotein Receptor Activity	Journal of clinical lipidology	Robert S. Rosenson, Frederick J. Raal et al.	1
6	LBP-10-A structurally engineered fatty acid, icosabutate, rapidly normalises elevated plasma ALTand gamma-glutamyl transferase (GGT) concentrations in a study population at high risk of NAFLD/NASH	Journal of Hepatology	David A. Fraser, Xiaoyu Wang et al.	1
7	A structurally engineered fatty acid, icosabutate, displays optimised absorption, distribution and metabolism properties for targeting hepatic inflammation and normalises elevated liver enzymes in dyslipidemic patients	Journal of Hepatology	David A. Fraser, J. Kastelein et al.	1
8	SAFETY AND EFFICACY OF LY3015014, A NEW MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) WITH AN INHERENTLY LONGER DURATION OF ACTION, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING, PHASE 2 STUDY	Journal of the American College of Cardiology	J. Kastelein, Steven Nissen et al.	8
9	EFFICACY AND SAFETY OF ROSUVASTATIN THERAPY FOR CHILDREN AND ADOLESCENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM THE CHARON STUDY	Journal of the American College of Cardiology	Gisle Langslet, Marjet J.A.M. Braamskamp et al.	0
10	Impact of a budget-restrictive (Germany) versus an incentive-driven (UK) reimbursement system on LDL-goal-achievement in statin-treated patients for secondary prevention: results of DYSIS	European Heart Journal	Anselm K. Gitt, Claus Juenger et al.	4
11	THE TRP719ARG VARIANT OF KIF6 AND CARDIOVASCULAR OUTCOMES IN STATIN-TREATED, CORONARY STABLE PATIENTS OF THE TNT AND IDEAL PROSPECTIVE STUDIES	Journal of the American College of Cardiology	Benoît Arsenault, S. Matthijs Boekholdt et al.	1
12	Triglycerides and Cardiovascular Risk	Current Cardiology Reviews	Karim El Harchaoui, Marjolein Visser et al.	102
13	Translating today's science into clinical practice	Atherosclerosis Supplements	Philip J. Barter, J. Kastelein	1
14	Clinical, Diagnostic, and Therapeutic Aspects of Familial Hypercholesterolemia	Seminars in Vascular Medicine	Emily Cohen, Angelique C.M. Jansen et al.	30
15	M.501 M-mode ultrasound imaging of arterial wall movement and arterial wall thickness of distal carotid arteries in atherosclerosis studies in healthy adults	Atherosclerosis Supplements	Frank M. Zijta, Wim J. Stok et al.	1
16	High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions	Atherosclerosis	Philip J. Barter, J. Kastelein et al.	164
17	Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands	The Lancet	Joep C. Defesche, Eric J.G. Sijbrands et al.	346
18	Measurement of atherosclerosis progression	The Lancet	Tineke J. Smilde, Sanne van Wissen et al.	1
19	Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women	Clinical Genetics	J. Kastelein, José M. Ordovás et al.	46
20	Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy	Nature Genetics	Stephan Rust, Michael Walter et al.	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact